Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1991-12-16
|
pubmed:abstractText |
Mometasone furoate (9 alpha, 21 dichloro-11 beta, 17 alpha dihydroxy-16 alpha methyl-1,4 pregnadiene-3, 20 dione-17-[2'] furoate) was an unexpectedly potent inhibitor of the in vitro production of three inflammatory cytokines, IL-1(1), IL-6, and TNF-alpha. The potency of mometasone furoate in inhibiting cytokine production was compared to that of hydrocortisone, betamethasone, dexamethasone, and beclomethasone. IL-6 and TNF-alpha were both produced by WEHI-265.1 (murine myelomonocytic leukemia) cells following stimulation by lipopolysaccharide (LPS). Twenty-four hours after stimulation by LPS, the cell-free supernatant fluids were removed. Their cytokine content was analyzed using ELISAs specific for each cytokine. IL-1 synthesis was induced in the harvested peritoneal macrophages of BALB/c mice by incubation with LPS for twenty-four hours. The IL-1 content in the cell-free supernatant fluids was determined by the thymocyte-costimulator bioassay. Using these systems, mometasone furoate was found to be the most potent steroid tested for inhibiting the production of the three cytokines. The IC50's were 0.05 nM (IL-1), 0.15 nM (IL-6), and 0.25 nM (TNF-alpha). The inhibition of the production of proinflammatory mediators by extremely low concentrations of mometasone furoate suggests that this steroid should be highly effective in various disorders.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Glucocorticoids,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Pregnadienediols,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/mometasone furoate
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0892-3973
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
13
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
251-61
|
pubmed:dateRevised |
2009-5-14
|
pubmed:meshHeading |
pubmed-meshheading:1940049-Administration, Topical,
pubmed-meshheading:1940049-Animals,
pubmed-meshheading:1940049-Anti-Inflammatory Agents,
pubmed-meshheading:1940049-Glucocorticoids,
pubmed-meshheading:1940049-Interleukin-1,
pubmed-meshheading:1940049-Interleukin-6,
pubmed-meshheading:1940049-Mice,
pubmed-meshheading:1940049-Pregnadienediols,
pubmed-meshheading:1940049-Tumor Cells, Cultured,
pubmed-meshheading:1940049-Tumor Necrosis Factor-alpha
|
pubmed:year |
1991
|
pubmed:articleTitle |
Cytokine inhibition by a novel steroid, mometasone furoate.
|
pubmed:affiliation |
Schering-Plough Research, Bloomfield, New Jersey 07003.
|
pubmed:publicationType |
Journal Article
|